Clinical Trial Detail

NCT ID NCT03988647
Title Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stanford University
Indications

Merkel cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.